Pharmacia's diagnostics climb 33% in first quarter of 1995:
This article was originally published in Clinica
Swedish-based pharmaceuticals manufacturer Pharmacia saw its allergy diagnostics business climb 33% to SKr 447 million ($62 million) in the 1995 first quarter. It attributes this to a positive trend in most markets - especially in Japan - where a high pollen count boosted demand. Consequently, Pharmacia's market shares have increased. Total first-quarter sales were SKr 6,436 million, down 5% on 1994, but when adjusted for divested operations, revenues were flat. Net income of SKr 825 million was up from SKr 782 million a year earlier.
You may also be interested in...
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.
Stada says it has become a "major consumer healthcare player" after signing a deal to acquire from GSK 15 brands, which generate annual sales of around €120m.